

Northwestern Memorial HealthCare and Subsidiaries

Quarterly Report

As of and for the Fourth Quarter Ended August 31, 2025

NORTHWESTERN MEMORIAL HEALTHCARE AND SUBSIDIARIES

Unaudited Condensed Consolidated Financial Statements As of and for the Fourth Quarter Ended August 31, 2025

CONTENTS

		1. 1 . 1		
Condence	d (once	Natenili	Financia	l Statements

Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations and Changes in Net Assets	3
Condensed Consolidated Statements of Cash Flows	5
Notes to the Condensed Consolidated Financial Statements	F

Northwestern Memorial HealthCare and Subsidiaries Condensed Consolidated Balance Sheets (Dollars in thousands)

		August 31, 2025		31,	
	(Unaudited)	Note	Α	
Assets					
Current Assets:					
Cash and cash equivalents	\$	885,327	\$ 33	32,319	
Short-term investments		376,726	64	47,510	
Current portion of investments, including assets limited as to use		284,634	29	97,385	
Patient accounts receivable		1,260,017	1,09	98,009	
Current portion of pledges and grants receivable, net		38,186	3	36,507	
Current portion of insurance recoverable		33,726	3	33,068	
Inventories		183,420	15	55,359	
Other current assets		374,269	30	01,678	
Total current assets		3,436,305	2,90	01,835	
Investments, including assets limited as to use, less current portion		11,636,563	10,73	35,303	
Property and equipment, at cost:					
Land		451,504	45	50,023	
Buildings		6,294,221	6,10	05,876	
Equipment and furniture		2,457,278	2,31	10,174	
Construction in progress		671,938	39	93,842	
		9,874,941	9,25	59,915	
Less accumulated depreciation and amortization		4,527,561	4,18	31,443	
		5,347,380	5,07	78,472	
Prepaid pension cost		229,416	22	26,264	
Pledges and grants receivable, less current portion		82,831	10	00,334	
Insurance recoverable, less current portion		129,553	16	57,271	
Operating lease right-of-use assets		215,620	18	39,896	
Other assets, net		631,064	40	06,552	
Total assets	\$	21,708,732	\$ 19,80	05,927	

Continued on next page.

Northwestern Memorial HealthCare and Subsidiaries Condensed Consolidated Balance Sheets (continued) (Dollars in thousands)

	August 31, 2025	August 31, 2024
	(Unaudited)	Note A
Liabilities and net assets		
Current Liabilities		
Accounts payable	\$ 431,146	\$ 367,593
Accrued salaries and benefits	695,749	626,770
Grants and academic support payable, current portion	18,556	36,828
Accrued expenses and other current liabilities	235,238	200,143
Due to third-party payors	784,422	671,668
Current accrued liabilities under self-insurance programs	240,559	249,186
Current maturities of long-term debt	22,095	80,555
Long-term debt subject to short-term remarketing	299,565	126,200
Short-term debt	55,000	
Total current liabilities	2,782,330	2,358,943
Long-term debt, less current maturities	1,476,242	1,674,994
Accrued liabilities under self-insurance programs, less current portion	1,088,244	1,007,139
Grants and academic support payable, less current portion	74,848	58,431
Interest rate swaps	28,391	35,933
Operating lease liabilities, less current portion	208,875	176,819
Other liabilities	490,765	450,447
Total liabilities	6,149,695	5,762,706
Net assets:		
Without donor restrictions:		
Controlling interest	14,704,530	13,255,770
Noncontrolling interest in subsidiaries	1,018	714
Total net assets without donor restrictions	14,705,548	13,256,484
With donor restrictions	853,489	786,737
Total net assets	15,559,037	14,043,221
Total liabilities and net assets	\$ 21,708,732	\$ 19,805,927

Note A: The August 31, 2024 financial statement information was derived from and should be read in conjunction with the Northwestern Memorial HealthCare and Subsidiaries 2024 audited consolidated financial statements.

See accompanying notes to the interim condensed consolidated financial statements.

Northwestern Memorial HealthCare and Subsidiaries Condensed Consolidated Statements of Operations and Changes in Net Assets (Unaudited)

(Dollars in thousands)

		Three Months Ended		Twelve Months Ended			
		Augu	ıst	31,	August		31,
		2025		2024	2025		2024
Revenue							
Patient service revenue	\$	2,504,419	\$	2,265,337	\$ 9,802,217	\$	8,883,682
Rental and other revenue		204,819		161,993	735,871		612,010
Net assets released from donor restrictions and							
federal and state grants	_	50,318		19,592	100,982		63,893
Total revenue		2,759,556		2,446,922	10,639,070		9,559,585
Expenses							
Salaries		1,159,026		1,055,570	4,422,692		4,039,164
Employee benefits		143,092		155,062	664,279		600,946
Supplies		680,876		597,647	2,580,368		2,232,752
Purchased services		274,198		254,070	981,651		887,990
Depreciation and amortization		112,806		112,479	427,539		405,070
Insurance		87,229		60,319	325,249		250,412
Rent and utilities		29,721		26,494	107,550		100,260
Repairs and maintenance		90,607		76,998	234,021		207,549
Interest		10,217		13,155	44,993		52,920
Illinois Hospital Assessment		59,219		58,501	236,730		234,515
Other		59,612		48,378	234,462		208,281
Total expenses		2,706,603		2,458,673	10,259,534		9,219,859
Operating income (loss)		52,953		(11,751)	379,536		339,726
Nonoperating gains (losses)							
Investment return		630,911		371,849	1,194,176		1,369,477
Change in fair value of interest rate swaps		(2,068)		(11,973)	7,542		(5,528)
Grants and academic support provided		(76,972)		(67,903)	(139,425)		(130,091)
Other, net		7,173		8,277	(11,126)		8,383
Total nonoperating gains, net		559,044		300,250	1,051,167		1,242,241
Excess of revenue over expenses		611,997		288,499	1,430,703		1,581,967
Net gain (loss) attributable to noncontrolling interest in subsidiaries		40		243	 916		(148)
Excess of revenue over expenses attributable to NMHC and subsidiaries	\$	611,957	\$	288,256	\$ 1,429,787	\$	1,582,115

Continued on next page.

Northwestern Memorial HealthCare and Subsidiaries Condensed Consolidated Statements of Operations and Changes in Net Assets (Unaudited)

(Dollars in thousands)

	(50	ilars ili tiloasaria	3)			
		Three Months	s Ended	Twelve Months Ended		
		August 3	31,	August 3	31,	
		2025	2024	2025	2024	
Net assets without donor restrictions, controlling interest						
Excess of revenue over expenses	\$	611,957 \$	288,256 \$	1,429,787 \$	1,582,115	
Net assets released from restrictions used for property and equipment additions		5,417	2,694	21,911	14,704	
Postretirement-benefit-related changes other than net periodic pension cost Other		(5,567) 1	(28,014) (5)	(2,923) (15)	(25,745) (90)	
Increase in net assets without donor restrictions, controlling interest		611,808	262,931	1,448,760	1,570,984	
Net assets without donor restrictions, noncontrolling interest						
Excess (deficiency) of revenue over expenses		40	243	916	(148)	
Distribution to noncontrolling interest Other		(127) (1)	(177) (5)	(611) (1)	(329) (5)	
(Decrease) increase in net assets without donor restrictions, noncontrolling interest		(88)	61	304	(482)	
Net assets with donor restrictions						
Contributions		9,596	15,266	132,407	88,066	
Investment return		12,001	10,679	44,426	35,247	
Net assets released from restrictions used for:						
Operating expenses, charity care, and research and education		(38,542)	(29,509)	(90,549)	(77,967)	
Property and equipment additions		(5,417)	(2,694)	(21,911)	(14,704)	
Change in fair value of split-interest agreements		1,279	729	2,404	1,841	
Other		(50)	(1,065)	(25)	(984)	
(Decrease) increase in net assets with donor restrictions		(21,133)	(6,594)	66,752	31,499	
Change in net assets		590,587	256,398	1,515,816	1,602,001	
Net assets, beginning of period		14,968,450	13,786,823	14,043,221	12,441,220	
Net assets, end of period	\$	15,559,037 \$	14,043,221 \$	15,559,037 \$	14,043,221	
, 1	÷	, , т	, , т	, , т	, -, -	

Northwestern Memorial HealthCare and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

Twelve Months Ended

Operating activities August 14, 2025 August 31, 2026 Change in net assets \$ 1,515,816 \$ 1,602,001 Adjustments to reconcile change in net assets to net cash used in persions octs. \$ 2,523 \$ 2,574 Adjustments to reconcile change in net assets to net cash used in persion octs. \$ 2,923 \$ 2,574 Postretirement benefit-related changes other than net periodic pension cost. \$ 2,923 \$ 2,574 Change in fair value of interest rate swaps \$ (1,86,978) \$ 1,368,177 Net unrestricted and restricted investment return and net change in unrestricted and restricted investment return \$ (1,92,37) \$ (126,465) Restricted contributions, change in fair value of split interest agreements and realized investment return \$ 427,59 \$ 405,000 Restricted contributions, change in fair value of split interest agreements and realized investment return \$ 427,59 \$ 405,000 Restricted contributions, change in fair value of split interest agreements and realized investment return \$ 119,237 \$ 126,646 Patient accounts receivable \$ (162,008) \$ 13,421 \$ 13,421 Patient accounts receivable \$ (182,008) \$ (186,008) \$ (186,008) \$ (186,008) \$ (186,008) \$ (186,008)		TWEIVE MIGHT	3 Eliaca	
Change in net assets \$ 1,515,816 \$ 1,602,001 Adjustments to reconcile change in net assets to net cash used in operating activities: Postretirement benefit-related changes other than net periodic pension cost \$ 2,923 \$ 25,745 \$ 1,602,001 Change in fair value of interest rate swaps \$ (7,542) \$ 5,528 \$ 1,606,005,000 \$ 1,186,978 \$		 August 31,	August 31,	
Change in net assets\$ 1,515,816 \$ 1,602,001Adjustments to reconcile change in net assets to net cash used in operating activities:\$ 2,92325,745Postretrement benefit-related changes other than net periodic pension cost2,92325,745Change in fair value of interest rate swaps(7,542)5,528Net unrestricted realized investment return and net change in unrestricted and restricted unrealized investment gains(1,186,978)(1,368,177)Restricted contributions, change in fair value of split interest agreements and realized investment return(179,237)(126,465)Depreciation and amortization427,539405,070Changes in operating assets and liabilities:(162,008)(134,212)Patient accounts receivable(162,008)(134,212)Due to third-party payors115,755(156,630)Grants and academic support payable(1,855)21,264Other operating assets and liabilities177,60936,668Net cash provided by operating activities702,022310,792Investing activities(6,308,227)(8,088,733)Purchase of investments(6,6308,227)(8,088,733)Sale of investments(6,6308,227)(684,653)Other investing activities(148,322)-Net cash used in investing activities(148,322)-Proceeds from commercial paper55,000-Proceeds from commercial paper55,000-Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest		2025	2024	
Adjustments to reconcile change in net assets to net cash used in operating activities: Postretirement benefit-related changes other than net periodic pension cost Change in fair value of interest rate swaps Net unrestricted realized investment return and net change in unrestricted and restricted unrealized investment gains unrestricted contributions, change in fair value of split interest agreements and realized investment return Representation and amortization (179,237) (126,465) Depreciation and amortization (179,237) (126,465) Depreciation and amortization (162,008) (134,212) Patient accounts receivable (162,008) (134,212) Due to third-party payors (156,630) Grants and academic support payable (1,855) (156,630) Other operating assets and liabilities (177,609) (36,688) Net cash provided by operating activities (177,609) (8,088,733) Purchase of investments (6,308,227) (8,088,733) Sale of investments (6,6308,227) (8,088,733) Charimsesting activities (148,322) — Net unrestricted realized investment return (1812,176) (194,645) Net cash used in investing activities (184,322) — Net unrestricted realized investment return (194,647) (684,653) Net cash used in investing activities (194,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return (199,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return (199,530) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return (199,530) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return (199,530) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return (199,530) (19,055)	Operating activities			
Postretirement benefit-related changes other than net periodic pension cost 2,923 25,745 Change in fair value of interest rate swaps (7,542) 5,528 Net unrestricted realized investment return and net change in unrestricted and restricted unrealized investment gains (1,186,978) (1,368,177) Restricted contributions, change in fair value of split interest agreements and realized investment return 427,539 405,070 Depreciation and amortization 427,539 405,070 Changes in operating assets and liabilities: Patient accounts receivable (162,008) (134,212) Due to third-party payors 115,755 (156,630) Grants and academic support payable (1,855) 21,264 Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities Purchase of investments (6,308,227) (8,088,733) Sale of investments (6,665,304) 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities 702,603 Forceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Change in net assets	\$ 1,515,816 \$	1,602,001	
pension cost 2,923 25,745 Change in fair value of interest rate swaps (7,542) 5,528 Net unrestricted realized investment return and net change in unrestricted and restricted unrealized investment gains (1,186,978) (1,368,177) Restricted contributions, change in fair value of split interest agreements and realized investment return (179,237) (126,465) Depreciation and amortization 427,539 405,070 Changes in operating assets and liabilities: \$\textstyle{\				
Net unrestricted realized investment return and net change in unrestricted and restricted unrealized investment gains(1,186,978)(1,368,177)Restricted contributions, change in fair value of split interest agreements and realized investment return(179,237)(126,465)Depreciation and amortization427,539405,070Changes in operating assets and liabilities:(162,008)(134,212)Pue to third-party payors115,755(156,630)Grants and academic support payable(1,855)21,264Other operating assets and liabilities177,60936,668Net cash provided by operating activities702,022310,792Investing activities702,022310,792Purchase of investments(6,308,227)(8,088,733)Sale of investments(6,65,304)7,585,694Other investing activities(148,322)—Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activities(79,535)(19,055)Proceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities553,008(348,065)Net increase (decrease) in cash and cash equivalents553,008(348,065)		2,923	25,745	
unrestricted and restricted unrealized investment gains (1,186,978) (1,368,177) Restricted contributions, change in fair value of split interest agreements and realized investment return (179,237) (126,465) Depreciation and amortization 427,539 405,070 Changes in operating assets and liabilities: 162,008 (134,212) Due to third-party payors 115,755 (156,630) Grants and academic support payable (1,855) 21,264 Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities (6,308,227) (8,088,733) Sale of investments (6,633,227) (8,088,733) Sale of investments (6,655,304) 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities 55,000 — Payments of long	Change in fair value of interest rate swaps	(7,542)	5,528	
agreements and realized investment return (179,237) (126,465) Depreciation and amortization 427,539 405,070 Changes in operating assets and liabilities:		(1,186,978)	(1,368,177)	
Changes in operating assets and liabilities:Patient accounts receivable(162,008)(134,212)Due to third-party payors115,755(156,630)Grants and academic support payable(1,855)21,264Other operating assets and liabilities177,60936,668Net cash provided by operating activities702,022310,792Investing activitiesPurchase of investments(6,308,227)(8,088,733)Sale of investments(6,655,304)7,585,694Other investing activities(148,322)-Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activitiesProceeds from commercial paper55,000-Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384		(179,237)	(126,465)	
Patient accounts receivable (162,008) (134,212) Due to third-party payors 115,755 (156,630) Grants and academic support payable (1,855) 21,264 Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities (6,308,227) (8,088,733) Sale of investments 6,065,304 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities 55,000 — Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents	Depreciation and amortization	427,539	405,070	
Due to third-party payors 115,755 (156,630) Grants and academic support payable (1,855) 21,264 Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities 8,088,733 48,088,733 Sale of investments 6,065,304 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities 55,000 — Poyments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Changes in operating assets and liabilities:			
Grants and academic support payable (1,855) 21,264 Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities 8 10,000 <td>Patient accounts receivable</td> <td>(162,008)</td> <td>(134,212)</td>	Patient accounts receivable	(162,008)	(134,212)	
Other operating assets and liabilities 177,609 36,668 Net cash provided by operating activities 702,022 310,792 Investing activities (6,308,227) (8,088,733) Purchase of investments 6,065,304 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities (303,716) (766,267) Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Due to third-party payors	115,755	(156,630)	
Net cash provided by operating activities 702,022 310,792 Investing activities (6,308,227) (8,088,733) Purchase of investments (6,065,304 7,585,694 Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities 79,535) (19,055) Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Grants and academic support payable	(1,855)	21,264	
Investing activitiesPurchase of investments(6,308,227)(8,088,733)Sale of investments6,065,3047,585,694Other investing activities(148,322)—Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activities55,000—Proceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384	Other operating assets and liabilities	177,609	36,668	
Purchase of investments(6,308,227)(8,088,733)Sale of investments6,065,3047,585,694Other investing activities(148,322)—Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activitiesProceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384	Net cash provided by operating activities	702,022	310,792	
Sale of investments6,065,3047,585,694Other investing activities(148,322)—Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activitiesProceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384	Investing activities			
Other investing activities (148,322) — Net unrestricted realized investment return 812,176 421,425 Capital expenditures, net (724,647) (684,653) Net cash used in investing activities (303,716) (766,267) Financing activities Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Purchase of investments	(6,308,227)	(8,088,733)	
Net unrestricted realized investment return812,176421,425Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activitiesProceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384	Sale of investments	6,065,304	7,585,694	
Capital expenditures, net(724,647)(684,653)Net cash used in investing activities(303,716)(766,267)Financing activitiesProceeds from commercial paper55,000—Payments of long-term debt(79,535)(19,055)Restricted contributions, change in fair value of split interest agreements and realized investment return179,237126,465Net cash provided by financing activities154,702107,410Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384	Other investing activities	(148,322)	_	
Net cash used in investing activities (303,716) (766,267) Financing activities Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Net unrestricted realized investment return	812,176	421,425	
Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Capital expenditures, net	 (724,647)	(684,653)	
Proceeds from commercial paper 55,000 — Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Net cash used in investing activities	(303,716)	(766,267)	
Payments of long-term debt (79,535) (19,055) Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Financing activities			
Restricted contributions, change in fair value of split interest agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Proceeds from commercial paper	55,000	_	
agreements and realized investment return 179,237 126,465 Net cash provided by financing activities 154,702 107,410 Net increase (decrease) in cash and cash equivalents 553,008 (348,065) Cash and cash equivalents, beginning of period 332,319 680,384	Payments of long-term debt	(79,535)	(19,055)	
Net increase (decrease) in cash and cash equivalents553,008(348,065)Cash and cash equivalents, beginning of period332,319680,384		179,237	126,465	
Cash and cash equivalents, beginning of period 332,319 680,384	Net cash provided by financing activities	154,702	107,410	
	Net increase (decrease) in cash and cash equivalents	553,008	(348,065)	
Cash and cash equivalents, end of the period \$ 885,327 \$ 332,319	Cash and cash equivalents, beginning of period	332,319	680,384	
	Cash and cash equivalents, end of the period	\$ 885,327 \$	332,319	

See accompanying notes to the interim condensed consolidated financial statements.

(Unaudited and in thousands)

1. Organization and Basis of Presentation

Northwestern Memorial HealthCare (NMHC) is the parent of an integrated nonprofit health care organization, anchored by Northwestern Memorial Hospital (NMH) and Northwestern Medical Group (NMG), that provides health care services to communities in northern Illinois. NMHC partners with Northwestern University's Feinberg School of Medicine (FSM) to form an academic medical center, branded as Northwestern Medicine, that is shaping the future of medicine through outstanding patient care, research and training of resident physicians.

The accompanying condensed consolidated financial statements include the accounts of NMHC and its subsidiaries (collectively referred to herein as Northwestern Memorial). All significant intercompany transactions and balances have been eliminated in consolidation.

These interim financial statements have not been audited; however, in the opinion of management, they include all adjustments necessary for their fair presentation in conformity with U.S. generally accepted accounting principles (U.S. GAAP). These interim statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the audited consolidated financial statements of Northwestern Memorial for the year ended August 31, 2024.

Interim results are not necessarily indicative of results for a full year or any future periods. The information included in these interim financial statements should be read in conjunction with the audited consolidated financial statements for the year ended August 31, 2024, which are available on the Electronic Municipal Market Access ("EMMA") website of the Municipal Securities Rulemaking Board.

2. Patient Service Revenue

Northwestern Memorial recognizes Patient service revenue at the amount that reflects the consideration expected to be paid for providing patient care. Patient service revenue is recognized as performance obligations are satisfied based on the nature of the services provided by Northwestern Memorial. Performance obligations satisfied over time relate to patients in Northwestern Memorial hospitals receiving inpatient acute care services from admission to the point when services are no longer required, which is generally at the time of discharge. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Outpatient services are performance obligations satisfied at a point in time and revenue is recognized when goods or services are provided and Northwestern Memorial does not believe it is required to provide additional goods or services. Management believes this method provides a fair depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations.

Northwestern Memorial has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) because all of its performance obligations relate to contracts with a duration of less than one year. Therefore, Northwestern Memorial is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

(Unaudited and in thousands)

Northwestern Memorial uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and major payor classes and types of services provided for outpatient revenue. Based on the historical collection trends and other analysis, Northwestern Memorial believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Northwestern Memorial determines the transaction price, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payors, discounts provided to uninsured and underinsured patients in accordance with policy and/or implicit price concessions based on the historical collection experience of patient accounts. Northwestern Memorial determines the transaction price associated with services provided to patients who have third-party payor coverage with Medicare, Medicaid, Blue Cross, other managed care programs and other third-party payors based on reimbursement terms per contractual agreements, discount policies and historical experience. Payment arrangements with those payors include prospectively determined rates per admission or visit, reimbursed costs, discounted charges per diem rates and value-based care agreements. Reported costs and/or services provided under certain of the arrangements are subject to retroactive audit and adjustment. Patient service revenue increased by \$15,533 and \$18,236 for the three months ended August 31, 2025 and 2024, respectively, and increased by \$39,242 and \$33,823 for the twelve months ended August 31, 2025 and 2024, respectively, as a result of changes in estimates due to settlements of prior fiscal years' cost reports and the disposition of other payor audits and settlements. Future changes in Medicare and Medicaid programs and reduction in funding levels could have an adverse effect on Northwestern Memorial. There were no other significant changes to the judgments used to determine the transaction price in prior periods.

Northwestern Memorial also provides care to self-pay patients. Under its Financial Assistance Policy (the Policy), Northwestern Memorial provides medically necessary care to patients in its community with inadequate financial resources at discounts of up to 100% of charges using a sliding scale that is based on patient household income as a percentage (up to 600%) of the federal poverty level guidelines. The Policy also contains a catastrophic financial assistance provision that limits a patient's total financial responsibility to Northwestern Memorial. Since Northwestern Memorial does not pursue collection of these amounts, the values are reported net of price concessions. Northwestern Memorial uses presumptive eligibility screening procedures for free care and recognizes Patient service revenue on services provided to self-pay patients at a reduced transaction price at the time services are rendered.

In certain instances, Northwestern Memorial receives payment in advance of the services provided and considers these amounts to represent contract liabilities. Contract liabilities at August 31, 2025 and August 31, 2024 were not material.

(Unaudited and in thousands)

Management has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the payors and line of business that renders services to patients. The composition of Patient service revenue by payor was as follows:

	Three Months	Ended	Twelve Months	s Ended
	August 3	1,	August 3	1,
	2025	2024	2025	2024
Medicare	\$ 801,168 \$	708,100 \$	3,018,549 \$	2,711,507
Medicaid	216,364	226,759	884,334	904,403
Blue Cross	972,552	864,514	3,820,420	3,431,522
Other managed care	441,628	383,093	1,718,901	1,547,669
Commercial and other	48,553	63,025	268,193	213,670
Self-pay	24,154	19,846	91,820	74,911
Total	\$ 2,504,419 \$	2,265,337 \$	9,802,217 \$	8,883,682

The composition of the Patient service revenue by service line was as follows:

	Three Months Ended			Twelve Months Ended			
		August 3:	1,	August 31,			
		2025	2024	2025	2024		
Hospitals	\$	1,873,332 \$	1,693,474 \$	7,323,649 \$	6,701,649		
Physician groups		605,470	554,967	2,394,678	2,116,755		
Other		25,617	16,896	83,890	65,278		
Total	\$	2,504,419 \$	2,265,337 \$	9,802,217 \$	8,883,682		

Northwestern Memorial grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. At August 31, 2025 and August 31, 2024, respectively, patient accounts receivable, including patient co-pays and deductibles by major primary payor source, were as follows:

	August 31,	August 31,
	2025	2024
Medicare	25%	24%
Medicaid	7%	8%
Blue Cross	33%	33%
Other managed care	20%	20%
Commercial and other	6%	7%
Self-pay Self-pay	9%	8%
	100%	100%

(Unaudited and in thousands)

3. Hospital Assessment Program

On April 9, 2022, the Illinois General Assembly unanimously approved HB 1950 which essentially extends the existing Illinois Hospital Assessment Program (HAP) for the State of Illinois through 2026. On May 17, 2022, HB 1950 was signed into law by the Governor as Illinois Public Law 102-866. The legislation maintains the HAP's current tax structure. The HAP program provides for increased Illinois Medicaid and Illinois Medicaid Managed Care inpatient rates focusing on patient volumes as well as acuity.

On September 23, 2025, the Illinois Department of Healthcare and Family Services notified Illinois Hospital Providers that the federal Centers for Medicare and Medicaid Services (CMS) approved the State's plan (Illinois Public Act 104-0007) to increase the HAP's Managed Care Access Payments (MCAPs) made to hospitals through the Illinois Managed Care Organizations. As a result, there is an update to the HAP's MCAPs retroactive to January 1, 2025. This plan also increases the monthly assessments paid by the hospitals. No amounts were recorded as of August 31, 2025 as a result of this change.

A summary of the amounts recognized for the HAP program is as follows:

	Three Months Ended			Twelve Months Ended			
		August 31	1,	August 31,			
		2025	2024	2025	2024		
Patient service revenue - HAP	\$	75,631 \$	81,455 \$	306,514 \$	312,547		
Illinois Hospital Assessment		(59,219)	(58,501)	(236,730)	(234,515)		
Net excess of HAP revenue over Illinois assessment	\$	16,412 \$	22,954 \$	69,784 \$	78,032		

4. Investments and Other Financial Instruments

The composition of investments, including assets limited as to use, and cash and cash equivalents and short-term investments, is as follows:

		August 31, 2025	August 31, 2024
Measured at fair value:			
Cash and cash equivalents and Short-term investments	\$	1,597,148 \$	1,240,192
Mutual funds		661,779	634,654
Corporate bonds		604,240	613,766
U.S. government and agency issues		689,628	593,261
Equity securities		329,175	368,864
Common collective trusts and commingled investments		1,764,077	1,830,469
Interest in 103-12 investment entities		415,255	370,467
	· <u> </u>	6,061,302	5,651,673
Accounted for under the equity method:			
Alternative investments		7,121,948	6,360,844
	\$	13,183,250 \$	12,012,517

(Unaudited and in thousands)

Investments, including assets limited as to use, and cash and cash equivalents and short-term investments, consist of the following:

	 August 31, 2025	August 31, 2024
Assets limited as to use:		_
Trustee-held funds	\$ 821 \$	841
Self-insurance programs	1,345,271	927,909
Board-designated funds	 3,710	3,421
Total assets limited as to use	1,349,802	932,171
Donor-restricted funds	731,226	648,499
Unrestricted, undesignated funds	 9,840,169	9,452,018
Total investments, excluding short-term investments	11,921,197	11,032,688
Other financial instruments:		
Cash and cash equivalents and short-term investments	 1,262,053	979,829
	\$ 13,183,250 \$	12,012,517

The composition and presentation of investment returns are as follows:

	Three Months Ended		Twelve Months Ended		
		August 3	1,	August 31,	
		2025	2024	2025	2024
Interest and dividend income	\$	39,809 \$	47,471 \$	153,421 \$	167,627
Investment expenses		(1,439)	(1,506)	(5,508)	(6,173)
Realized gains on alternative investments, net		125,032	41,221	340,384	148,279
Realized gains on other investments, net		61,211	200,682	410,121	203,086
Net change in unrealized gains on alternative investments		170,624	92,587	421,938	526,456
Net change in unrealized (losses) gains on other investments		259,293	16,189	(39,938)	420,295
Change in value of joint ventures		555	520	1,763	1,616
	\$	655,085 \$	397,164 \$	1,282,181 \$	1,461,186
Reported as:					_
Rental and other revenue	\$	12,173 \$	14,636 \$	43,579 \$	56,462
Nonoperating investment return		630,911	371,849	1,194,176	1,369,477
With donor restriction investment return		12,001	10,679	44,426	35,247
	\$	655,085 \$	397,164 \$	1,282,181 \$	1,461,186

(Unaudited and in thousands)

Commingled investments, common collective trusts and 103-12 investment entities are commingled funds formed from the pooling of investments under common management. Unlike a mutual fund, these investments are not registered investment companies and therefore are exempt from registering with the Securities and Exchange Commission.

The investment strategy for the mutual funds, commingled investments, common collective trusts and 103-12 investment entities involves maximizing the overall long-term return by investing in a wide variety of assets, including domestic large cap equities, domestic small cap equities, international developed equities, blended equities, (i.e., a mix of domestic and international equities), natural resources and private investment limited partnerships (LPs).

Northwestern Memorial's non-pension plan investments measured under the equity method of accounting, using net asset value, include absolute return hedge funds, equity long/short hedge funds, real estate, natural resources and LPs, collectively referred to as alternative investments. Alternative investments in the pension plan assets are measured at fair value.

Absolute return hedge funds include funds with the ability to opportunistically allocate capital among several strategies. Generally, these funds diversify across strategies in an effort to deliver consistently positive returns regardless of the movement within global markets, exhibit relatively low volatility and are redeemable quarterly with a 60-day notice period. Equity long/short hedge funds include hedge funds that invest both long and short in U.S. and international equities. These funds typically focus on diversifying or hedging across particular sectors, regions or market capitalizations and are generally redeemable quarterly with a 60-day notice period.

Real estate includes LPs that invest in land and buildings and seek to improve property level operations by increasing lease rates, recapitalizing properties, rehabilitating aging/distressed properties and repositioning properties to maximize revenue. Real estate LPs typically use moderate leverage. Natural resources include a diverse set of LPs that invest in oil and natural gas-related companies, commodity-oriented companies and timberland. Private equity includes LPs formed to make equity and debt investments in operating companies that are not publicly traded. These LPs typically seek to influence decision-making within the operating companies. Investment strategies in this category may include venture capital, buyouts and distressed debt. These three categories of investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying assets of the fund are expected to be liquidated periodically over the lives of the LPs, which generally run 10 to 12 years.

Because of the timing of the preparation and delivery of financial statements for limited partnership investments, the use of the most recently available financial statements provided by the general partners results in a two month delay in the inclusion of the limited partnership results in Northwestern Memorial's condensed consolidated statements of operations and changes in net assets due to results recorded based on June 30 investment statements. Due to this delay, these condensed consolidated financial statements do not yet reflect the market conditions experienced in the last two months of the fourth quarter of fiscal 2025 or fiscal 2024 for the limited partnership investments.

As of August 31, 2025, \$5,162,505 of alternative investments is subject to various redemption limits and lockup provisions, of which \$4,578,186 expires within one year and \$584,319 expires after one year from the balance sheet date.

At August 31, 2025, Northwestern Memorial had commitments to fund approximately an additional \$1,180,000 to alternative investment entities. This funding is expected to occur over the next 12 years.

(Unaudited and in thousands)

5. Fair Value Measurements

Northwestern Memorial follows the requirements of ASC 820, Fair Value Measurement, in regard to measuring the fair value of certain assets and liabilities, as well as disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received for an asset or paid for a transfer of a liability in an orderly transaction on the measurement date.

The methodologies used to determine the fair value of assets and liabilities reflect market participant objectives and are based on the application of a three-level valuation hierarchy that prioritizes observable market inputs over unobservable inputs. The three levels are defined as follows:

- Level 1 Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in
 active markets and inputs that are observable for the asset or liability, either directly or indirectly,
 for substantially the full term of the financial instrument. Examples of Level 2 inputs are quoted
 prices for similar assets or liabilities in inactive markets or pricing models with inputs that are
 observable for substantially the full term of the asset or liability.
- Level 3 Inputs to the valuation methodology are significant to the fair value of the asset or the liability and less observable. These inputs reflect the assumptions market participants would use in the estimation of the fair value of the asset or liability.

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input that is significant to their fair value measurement.

(Unaudited and in thousands)

The following table presents the financial instruments measured at fair value on a recurring basis at August 31, 2025:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash and cash equivalents	\$ 885,327	\$ —	\$ -	\$ 885,327
Investments:				
Short-term investments:				
Cash equivalents in investment accounts	2,197	_	_	2,197
Mutual fund - fixed income	84,109	_	_	84,109
U.S. government and agency issues		290,420	_	290,420
Total short-term investments	86,306	290,420	_	376,726
Mutual funds:				
Fixed income	48	_	_	48
International equities	253,178	_	_	253,178
U.S. equities	408,553	_	_	408,553
Total mutual funds	661,779	_	_	661,779
Common collective trusts and commingled investments:				
International equities	374,466	_	_	374,466
U.S. equities	1,389,611			1,389,611
Total common collective trusts and commingled investments	1,764,077	_	_	1,764,077
103-12 entities:				
International equities	415,255	_	_	415,255
Bonds:				
Corporate bonds	_	604,240	_	604,240
U.S. government and agency issues		689,628	_	689,628
Total bonds	_	1,293,868	_	1,293,868
Equity securities	329,175	_	_	329,175
Cash equivalents in investment accounts	523,358	_	_	523,358
Due to broker	(188,263)	_	_	(188,263)
Total investments	3,591,687	1,584,288	_	5,175,975
Beneficial interest in trusts		22,762		22,762
Total assets measured at fair value	\$ 4,477,014	\$ 1,607,050	\$ —	\$ 6,084,064
Liabilities:				
Interest rate swaps	\$ -	\$ 28,391	\$ -	\$ 28,391

(Unaudited and in thousands)

The following table presents the financial instruments measured at fair value on a recurring basis at August 31, 2024:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash and cash equivalents	\$ 332,319	\$ -	\$ -	\$ 332,319
Investments:				
Short-term investments:				
Cash equivalents in investment accounts	1,093	_	_	1,093
Mutual fund - fixed income	375,347	_	_	375,347
U.S. government and agency issues		271,070	_	271,070
Total short-term investments	376,440	271,070	_	647,510
Mutual funds:				
Fixed income	10,043	_	_	10,043
International equities	119,504	_	_	119,504
U.S. equities	505,107	_	_	505,107
Total mutual funds	634,654	_	_	634,654
Common collective trusts and commingled investments:				
International equities	417,421	_	_	417,421
U.S. equities	1,413,048	_		1,413,048
Total common collective trusts and commingled investments	1,830,469	_	_	1,830,469
103-12 entities:				
International equities	370,467	_	_	370,467
Bonds:				
Corporate bonds	_	613,766	_	613,766
U.S. government and agency issues		593,261		593,261
Total bonds	_	1,207,027	_	1,207,027
Equity securities	368,864	_	_	368,864
Cash equivalents in investment accounts	395,467	_	_	395,467
Due to broker	(135,104)	_	_	(135,104)
Total investments	3,841,257	1,478,097	_	5,319,354
Beneficial interest in trusts		20,358	_	20,358
Total assets measured at fair value	\$ 4,173,576	\$ 1,498,455	\$ —	\$ 5,672,031
Liabilities				
Liabilities:	¢ .	\$ 35,933	Ċ -	¢ 25.022
Interest rate swaps	\$ -	φ 55,933	\$ -	\$ 35,933

(Unaudited and in thousands)

Reconciliation to the Condensed Consolidated Balance Sheets

A reconciliation of the fair value of financial assets to the condensed consolidated balance sheets is as follows:

	,	August 31, 2025	August 31, 2024
Short-term investments measured at fair value	\$	376,726 \$	647,510
Investments, including assets limited as to use measured at fair value		4,799,249	4,671,844
Total investments at fair value		5,175,975	5,319,354
Alternative investments accounted for under equity method included in investments, including assets limited as to use		7,121,948	6,360,844
Total investments	\$	12,297,923 \$	11,680,198
Pledges and grants receivable, less current portion: Beneficial interests in trusts at fair value Pledges and grants receivable, less current portion, net	\$	22,762 \$ 60,069	20,358 79,976
	_	•	
Total pledges and grants receivable, less current portion	<u> </u>	82,831 \$	100,334

Valuation Techniques and Inputs

Beneficial Interests in Trusts - The fair value of beneficial interests in trusts is based on Northwestern Memorial Foundation's (the Foundation) percentage of the fair value of the trusts' assets adjusted for any outstanding liabilities (discounted using a rate per Internal Revenue Service (IRS) regulations), based on each trust arrangement.

Interest Rate Swaps - The fair value of interest rate swaps is based on generally accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative and quoted prices from dealer counterparties and other independent market sources. The valuation incorporates observable interest rates and yield curves for the full term of the swaps. The valuation is also adjusted to incorporate nonperformance risk for NMHC or the respective counterparty. The adjustment is based on the credit spread for entities with similar credit characteristics as NMHC or market-related data for the respective counterparty. Northwestern Memorial pays various fixed rates and receives cash flows based on rates equal to a percentage of the Secured Overnight Financing Rate (SOFR) plus a spread for certain interest rate swaps.

Investments - The fair value of Level 1 investments, which consist of equity securities, mutual funds, commingled investments, common collective trusts, and 103-12 investment entities is based on quoted market prices that are valued on a daily basis. Level 2 investments consist of U.S. government and agencies' issues and corporate bonds. The fair value of the U.S. government and agencies' issues and corporate bonds is established based on values obtained from nationally recognized pricing services that value the investments based on similar securities and matrix pricing of similar quality and maturity securities.

Northwestern Memorial's investments are exposed to various kinds and levels of risk. Equity securities and equity mutual funds expose Northwestern Memorial to market risk, performance risk and liquidity risk. Market risk is the risk associated with major movements of the equity markets. Performance risk is the risk

(Unaudited and in thousands)

associated with a company's operating performance. Fixed income securities and fixed income mutual funds expose Northwestern Memorial to interest rate risk, credit risk and liquidity risk. As interest rates change, the value of many fixed income securities is affected, including those with fixed interest rates. Credit risk is the risk that the obligor of the security will not fulfill its obligations. Liquidity risk is affected by the willingness of market participants to buy and sell particular securities. Liquidity risk tends to be higher for equities related to small capitalization companies and certain alternative investments. Due to the volatility in the capital markets, there is a reasonable possibility of subsequent changes in fair value, resulting in additional gains and losses in the near term.

The carrying values of cash and cash equivalents, accounts receivable, current portion of pledges and grants receivable, accounts payable, accrued expenses and other current liabilities and short-term borrowings are reasonable estimates of their fair values due to their short-term nature.

6. Long-Term Debt

Long-term debt consists of the following:

	P	August 31, 2025	August 31, 2024
Taxable Revenue Bonds, Series 2021 (NMHC), payable in varying installments beginning July 2030 through July 2051 (fixed coupon rates range from 1.67% to 2.63%)	\$	519,735	\$ 519,735
Revenue Bonds, Series 2021A (NMHC), payable in varying installments through July 2043 (fixed coupon rates range from 2.25% to 5.00%)		209,350	209,350
Revenue Bonds, Series 2017A (NMHC), payable in varying annual installments through July 2047 (fixed coupon rates range from 3.00% to 5.00%)		437,680	459,330
Revenue Bonds, Series 2017B (NMHC), payable in varying annual installments through July 2057 (fixed coupon rate of 3.54% through December 14, 2032)		162,380	162,380
Revenue Bonds, Series 2015E (NMHC), payable in varying annual installments through May 2037 (fixed coupon rate of 2.32% through September 30, 2025)		29,045	30,355
Variable Rate Demand Revenue Bonds, Series 2021B (NMHC), payable in annual installments through July 15, 2055 (weighted average interest rate of 2.66% and 3.24% for the twelve months ended August 31, 2025 and 2024, respectively)		73,000	73,000
Variable Rate Demand Revenue Bonds, Series 2021C (NMHC), payable in annual installments through July 15, 2055 (weighted average interest rate of 2.65% and 3.24% for the twelve months ended August 31, 2025 and 2024, respectively)		73,000	73,000
Variable Rate Demand Revenue Bonds, Series 2021D (NMHC), payable in annual installments through July 15, 2055 (weighted average interest rate of 2.78% and 3.47% for the twelve months ended August 31, 2025 and		60.46 7	
2024, respectively)		63,100	63,100

(Unaudited and in thousands)

	P	August 31, 2025	August 31, 2024
Variable Rate Demand Revenue Bonds, Series 2021E (NMHC), payable in annual installments through July 15, 2055 (weighted average interest rate of 2.74% and 3.47% for the twelve months ended August 31, 2025 and 2024, respectively)	\$	63,100 \$	63,100
Revenue Bonds, Series 2014B (NMHC), with interest at a variable rate payable with varying installments through September 2044, (weighted average interest rate of 4.05% and 4.74% for the twelve months ended August 31, 2025 and 2024, respectively)		31,655	31,655
Revenue Bonds, Series 2011A and 2011B (NMHC), with interest at a variable rate payable with varying annual installments through November 2038, (weighted average interest rate of 4.05% and 4.77% for the twelve months ended August 31, 2025 and 2024, respectively)		103,125	104,700
NMHC fixed rate note dated August 29, 2019, matured September 1, 2024 (fixed rate of 1.98%)		_	55,000
Palos Health Surgery Center promissory note, matures July 1, 2026 (fixed coupon rate of 5.00%)		1,275	1,275
NMHC commercial paper dated September 3, 2024 (weighted average interest rate of 4.57% for the twelve months ended August 31, 2025)		55,000	
		1,821,445	1,845,980
Less:			
Unamortized premium and debt issuance costs		(31,457)	(35,769)
Long-term debt subject to short-term remarketing agreements		299,565	126,200
Current maturities		22,095	80,555
Commercial paper, included in Short-term debt		55,000	_
	\$	1,476,242 \$	1,674,994

Northwestern Memorial has lines of credit with multiple banks. Northwestern Memorial has the option to borrow at various rates expressed as an adjustment to SOFR, prime rate or other bank-offered rates. Additionally, Northwestern Memorial has restricted certain lines of credit to secure letters of credit.

The amounts available, outstanding and restricted to secure letters of credit as of August 31, 2025 are as follows:

Available		 Outstanding Restricted		Restricted
\$	100,000	\$. \$	-
	7,000		-	2,763

(Unaudited and in thousands)

Northwestern Memorial has standby bond purchase agreements (SBPAs) with two banks that cover certain variable rate demand revenue bonds (VRDBs). The short-term credit rating for each series of VRDBs is based on the respective bank's short-term credit rating. The long-term credit rating for each series of VRDBs is based on Northwestern Memorial's long-term credit rating. Changes in credit ratings may impact the interest paid, on or remarketing of, the VRDBs. As of August 31, 2025, the banks provided liquidity support in the event of a failed remarketing as follows:

	Par Value	Expiration date
Subseries 2021B	73,000	August 2026
Subseries 2021C	73,000	August 2026

Northwestern Memorial provides self-liquidity on the Series 2021D and Series 2021E Bonds. These bonds are classified as Long-term debt subject to short-term remarketing in the accompanying condensed consolidated balance sheets.

The SBPAs include reporting and financial requirements and other covenants. If an SBPA is not renewed or replaced prior to its expiration, or if some portion, or all of the related VRDBs are not successfully remarketed (i.e., failed remarketing) during the term of the SBPA, the related VRDBs are Purchased Bonds by the SBPA provider under the SBPA. Such Purchased Bonds are required to be redeemed by the Obligated Group over an amortization period pursuant to the SBPA. The earliest redemption associated with the Purchased Bonds is 367 days from the failed remarketing date or the expiration date of the SBPA. Therefore, the VRDBs that are supported by SBPAs are classified as long-term debt in the accompanying condensed consolidated balance sheets.

The Series 2015E Bonds were subject to a put option during the initial private placement rate period ending on September 30, 2025, at which time the bonds were purchased from the bondholder and redeemed in full.

7. Derivatives

To manage fluctuations in cash flows resulting from interest rate risk, Northwestern Memorial entered into various interest rate swap agreements. By using interest rate swaps to manage the risk of changes in interest rates, Northwestern Memorial exposes itself to credit risk and market risk. Credit risk is the risk that a counterparty will fail to perform under the terms of a derivative contract. When the fair value of a swap is positive, the counterparty owes Northwestern Memorial, which creates credit risk for Northwestern Memorial. When the fair value of a swap is zero or negative, the counterparty does not owe Northwestern Memorial. Northwestern Memorial minimizes the credit risk in its swap contracts by entering into transactions that either require the counterparty to post collateral for the benefit of Northwestern Memorial based on the credit rating of the counterparty and the fair value of the swap contract or whose cash flows are insured by a third party. For certain interest rate swaps, Northwestern Memorial is required to post collateral for the benefit of the counterparty when the negative fair value of the swap exceeds a defined threshold. The aggregate fair value liability of the swaps on the condensed consolidated balance sheets reflect a reduction of \$401 and \$654 for nonperformance risk at August 31, 2025 and August 31, 2024, respectively. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. Management also mitigates risk through periodic reviews of its swap positions in the context of their total blended cost of capital.

(Unaudited and in thousands)

The following is a summary of the outstanding positions under existing interest rate swap agreements:

Notional Amount

A	August 31, 2025		ugust 31, 2024	Maturity Date	Rate Paid	Rate Received
\$	96,350	\$	97,200	August 2042	3.89 %	63% of 1-Month Fallback SOFR + 28 bps
	96,350		97,200	August 2042	3.89	63% of 1-Month Fallback SOFR + 28 bps
	57,925		58,300	November 2038	3.82	67% of 3-Month Fallback SOFR
	57,925		58,300	November 2038	3.52	67% of 3-Month Fallback SOFR
\$	308,550	\$	311,000			

The fair value of derivative instruments is as follows:

	Derivative Liabilities						
	Balance Sheet Location	August 31, 2025	August 31, 2024				
Derivatives not designated as hedging instruments:							
Interest rate contracts	Interest rate swap liabilities	\$ 28,391	\$ 35,933				

The effects of derivative instruments on the condensed consolidated statements of operations and changes in net assets are as follows:

		Three Months Ended August 31,		Twelve Months Ended August 31,	
		2025	2024	2025	2024
Derivatives not designated as hedging instruments:					
Nonoperating - investment return	\$	(545) \$	(38) \$	(1,833) \$	(243)
Nonoperating - change in fair value of interest rate swaps		(2,068)	(11,973)	7,542	(5,528)

Northwestern Memorial's derivative instruments contain provisions that require its debt to remain above certain credit ratings from Standard & Poor's and Moody's. If Northwestern Memorial's debt were to fall below those levels, it would be in violation of these provisions and the counterparties to the derivative instruments could request immediate payment or demand immediate and ongoing full overnight collateralization on derivative instruments in net liability positions. Northwestern Memorial has posted no collateral as of August 31, 2025 and August 31, 2024. If the credit-risk-related contingent features underlying the agreement were triggered to the fullest extent on August 31, 2025, Northwestern Memorial would be required to post \$28,792 of additional collateral to its counterparties.

(Unaudited and in thousands)

8. Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes as follows:

	August 31, 2025		August 31, 2024	
Subject to expenditure for specified purpose:				
Purchase of property and equipment	\$	64,394 \$	42,133	
Operating expenses and charity care		297,895	275,858	
Research, education and other		220,777	211,669	
Total expenditure for specified purpose		583,066	529,660	
Subject to passage of time:				
Pledges and trusts		1,888	2,310	
Endowments:				
Perpetual in nature:				
Purchase of property and equipment		16,004	16,004	
Operating expenses and charity care		117,791	115,111	
Research, education and other		134,740	123,652	
Total perpetual in nature		268,535	254,767	
Total net assets with donor restrictions	\$	853,489 \$	786,737	

Net assets were released from donor restrictions by incurring expenditures for the following purposes as follows:

	Three Months Ended August 31,			Twelve Months Ended August 31,		
		2025	2024	2025	2024	
Health care services:						
Purchase of property and equipment	\$	5,417 \$	2,694 \$	21,911 \$	14,704	
Clinical expenses and charity care		16,306	11,697	49,874	37,443	
Research, education and other		22,236	17,812	40,675	40,524	
	\$	43,959 \$	32,203 \$	112,460 \$	92,671	

Net assets released from donor restrictions reported in the condensed consolidated statements of operations and changes in net assets were recorded as follows:

	Three Months	Ended	Twelve Months Ended		
	August 31	L,	August 31,		
	2025	2024	2025	2024	
Net assets released from donor restrictions and federal and state grants	\$ 22,379 \$	17,415 \$	70,665 \$	56,999	
Nonoperating other	16,163	12,094	19,884	20,968	
	\$ 38,542 \$	29,509 \$	90,549 \$	77,967	

(Unaudited and in thousands)

Northwestern Memorial's endowment consists of individual donor-restricted funds established for a variety of purposes. Net assets associated with endowment funds are classified and reported based on the donor-imposed restrictions.

Northwestern Memorial has interpreted the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA), as adopted by the State of Illinois, as requiring the preservation of the value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, Northwestern Memorial classifies as net assets with restrictions the original value of gifts donated to the permanent endowment, the original value of subsequent gifts to the permanent endowment and accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time.

In accordance with UPMIFA, Northwestern Memorial considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

- The duration and preservation of the fund
- The purposes of Northwestern Memorial and the endowment fund
- General economic conditions
- The possible effects of inflation and deflation
- The expected total return from investment income
- Other resources of Northwestern Memorial
- The investment policies of Northwestern Memorial

Northwestern Memorial has adopted investment and spending policies for endowment assets designed to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that must be held in perpetuity or for a donor-specified period. Under this policy, endowment assets are allocated a fixed annual return, which is currently set at 7%.

Northwestern Memorial has a policy that generally limits annual spending from endowment funds to 5% of the endowment fund balance at the midpoint of the preceding fiscal year. In establishing this policy, Northwestern Memorial considered the long-term expected return on its endowment. Accordingly, over the long term, Northwestern Memorial expects the spending policy to allow its endowment to grow at an average annual rate of 2%. This is consistent with its objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

(Unaudited and in thousands)

The changes in endowment net assets for the twelve months ended August 31, 2024 and twelve months ended August 31, 2025 are summarized below:

	 Total
Endowment net assets, August 31, 2023	\$ 338,411
Contributions	6,051
Change in value of trusts	597
Investment return	20,107
Appropriation for expenditure	(11,637)
Other	(2,003)
Endowment net assets, August 31, 2024	\$ 351,526
Contributions	11,459
Change in value of trusts	1,967
Investment return	24,167
Appropriation for expenditure	(11,635)
Other	1,072
Endowment net assets, August 31, 2025	\$ 378,556

9. Pledges Receivable

As of August 31, 2025. donor-restricted pledges, which are included in Current portion of pledges and grants receivable, net and Pledges and grants receivable, less current portion, are expected to be realized as follows:

	Αι	igust 31, 2025
Less than one year	\$	35,964
One to five years		65,239
Thereafter		10,636
Total pledges receivable		111,839
Less allowances		(1,464)
Less present value discount		(14,342)
Net pledges receivable	\$	96,033

(Unaudited and in thousands)

10. Liquidity and Availability

Financial assets available for general expenditure within one year of the balance sheet date comprise the following:

	 August 31, 2025	August 31, 2024
Cash and cash equivalents	\$ 885,327 \$	332,319
Patient accounts receivable	1,260,017	1,098,009
Grants receivable	2,222	1,765
Other receivables	199,885	144,094
Investments	 10,982,378	10,345,177
Total financial assets available within one year	\$ 13,329,829 \$	11,921,364

11. Self-Insurance Programs and Related Insurance Recoverable

Northwestern Memorial's self-insurance liabilities and the related amount recoverable from reinsurers are reported in the accompanying condensed consolidated balance sheets at present value based on a discount rate of 3.0% and 2.5% as of August 31, 2025 and August 31, 2024, respectively. This discount rate is based on several factors, including rolling averages of risk-free rates based on estimated payment patterns of the underlying liability. Provisions for the professional and general liability risks are based on an actuarial estimate of losses using actual loss data adjusted for industry trends and current conditions and an evaluation of claims by Northwestern Memorial's legal counsel. The provision for estimated self-insured claims includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

12. Employee Benefit Obligations

Northwestern Memorial's non-contributory, defined-benefit pension plans (Plans) cover certain Northwestern Memorial employees employed prior to January 1, 2013 in NMHC, NMH and Northwestern Lake Forest Hospital (NLFH). The Plans were hard frozen as of December 31, 2012, such that no participant will earn any additional or new benefits under the Plans on or after January 1, 2013.

(Unaudited and in thousands)

Net periodic pension benefit included in Nonoperating gains (losses) Other in the accompanying condensed consolidated statements of operations and changes in net assets is comprised of the following:

		Three Months	Ended	Twelve Months Ended			
		August 3:	1,	August 31,			
	2025		2024	2025	2024		
Plan expenses	\$	(868) \$	(498) \$	(3,484) \$	(1,995)		
Interest cost on projected benefit obligation		(6,464)	(6,769)	(25,853)	(27,088)		
Expected return on Plan's assets		9,721	11,229	38,890	44,928		
Amortization of net loss		(877)	(639)	(3,508)	(2,559)		
	\$	1,512 \$	3,323 \$	6,045 \$	13,286		

Northwestern Memorial made no contributions for the twelve months ended August 31, 2025 and 2024, and has no current plans to contribute to the Plans during the fiscal year ending August 31, 2026.

Northwestern Memorial uses the spot rate approach to measure the service and interest cost. This method does not apply to the service cost as both plans have been frozen, but results in different discount rates utilized for purposes of measuring the interest cost of the two plans.

In February 2024, the Board of Directors of Northwestern Memorial approved the termination of the Plans. Northwestern Memorial will purchase annuities on behalf of the plan participants to the extent participants elect not to receive a distribution prior to the liquidation of the plan.

13. Functional Expenses

Northwestern Memorial provides general health care services primarily to residents within its geographic location and supports research and education programs. Operating expenses directly attributable to a specific functional area are reported as expenses of those functional areas. Expenses other than depreciation expense are directly allocated to functional departments at the time they are incurred. Depreciation expense is allocated on a pro rata basis. General, administrative and other expenses primarily include legal, finance, purchasing, human resources, information technology, management and governance.

(Unaudited and in thousands)

Expenses related to providing these services were as follows for the twelve months ended:

August 31, 2025

		th Care vices	General Research and Administra Education and Othe			
Salaries	\$ 3,	737,214	\$ 8,936	\$ 676,542	\$ 4,422,692	
Employee benefits	į	36,371	1,867	126,041	664,279	
Supplies	2,5	552,179	869	27,320	2,580,368	
Purchased services	3	327,780	21,728	632,143	981,651	
Depreciation and amortization	3	332,520	6,508	88,511	427,539	
Insurance	2	270,368	_	54,881	325,249	
Rent and utilities		54,761	9	52,780	107,550	
Repairs and maintenance	-	158,011	57	75,953	234,021	
Interest		375	_	44,618	44,993	
Illinois Hospital Assessment	2	236,730	_	_	236,730	
Other		50,199	122,702	61,561	234,462	
	\$ 8,2	256,508	\$ 162,676	\$ 1,840,350	\$ 10,259,534	

August 31, 2024

		lealth Care Services	Research and Education	General, Administrative and Other	dministrative	
Salaries	\$	3,366,272	\$ 8,022	\$ 664,870	\$	4,039,164
Employee benefits		478,305	1,790	120,851		600,946
Supplies		2,207,431	788	24,533		2,232,752
Purchased services		280,916	20,388	586,686		887,990
Depreciation and amortization		310,575	6,509	87,986		405,070
Insurance		190,689	_	59,723		250,412
Rent and utilities		49,186	9	51,065		100,260
Repairs and maintenance		136,153	82	71,314		207,549
Interest		261	_	52,659		52,920
Illinois Hospital Assessment		234,515	_	_		234,515
Other		41,824	117,064	49,393		208,281
	\$	7,296,127	\$ 154,652	\$ 1,769,080	\$	9,219,859

Northwestern Memorial had fundraising expenses of \$18,403 and \$12,419 for the twelve months ended August 31, 2025 and 2024, respectively, and are included in Nonoperating gains (losses) Other in the accompanying condensed consolidated statements of operations and changes in net assets.

(Unaudited and in thousands)

14. Commitments and Contingencies

Academic, Program and Other Support

Consistent with its mission, Northwestern Memorial provides academic, program and other support to other not-for-profit entities. The present value of the total remaining commitments related to this support is \$93,404 and \$95,259 at August 31, 2025 and August 31, 2024, respectively, which is reported as Grants and academic support payable, current portion and Grants and academic support payable, less current portion in the accompanying condensed consolidated balance sheets.

Northwestern Memorial will provide continuing funding to Northwestern University in support of the research and education mission of FSM. This continuing funding is based on the average Patient service revenue and operating results of Northwestern Memorial. The expense incurred of \$23,979 and \$20,564 for the three months ended August 31, 2025 and 2024, respectively, and \$118,265 and \$113,943 for the twelve months ended August 31, 2025 and 2024, respectively, is recorded in Other expense in the accompanying condensed consolidated statements of operations and changes in net assets; a related liability of \$1,026 and \$271 is recorded in Accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets as of August 31, 2025 and August 31, 2024, respectively.

Capital Projects

Various capital projects are currently being constructed and are expected to be placed in service over the next three years. The total estimated cost of these projects is approximately \$2,327,000. As of August 31, 2025, project commitments totaled \$1,889,000, of which \$1,486,000 has been incurred.

Regulatory

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is a reasonable possibility that recorded amounts will change by a material amount in the near term. During the last few years, as a result of nationwide investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties and potential exclusion from the Medicare and Medicaid programs.

In addition, an increasing number of the operations and practices of not-for-profit health care providers has been challenged or questioned to determine whether they are consistent with the regulatory requirements for nonprofit tax-exempt organizations. These challenges are broader than concerns about compliance with federal and state statutes and regulations of core business practices of the health care organizations. The laws and regulations regarding these practices are also subject to interpretation and challenge. Areas that have come under examination have included pricing practices, billing and collection practices, charity care, community benefit, executive compensation and exemption of property from real property taxation. Northwestern Memorial expects that the level of review and audit to which it and other health care providers are subject will increase. There can be no assurance that regulatory authorities will not challenge Northwestern Memorial's compliance with these laws and regulations or that the laws and regulations themselves will not be subject to challenge, and it is not possible to determine the impact, if any, such claims, penalties or challenges would have on Northwestern Memorial.

(Unaudited and in thousands)

The United States Department of Health and Human Services Office of Civil Rights (OCR) is responsible for enforcing the Health Insurance Portability and Accountability Act (HIPAA) and the Privacy and Security Rules. Northwestern Memorial is aware of, has investigated, and has made disclosure to OCR with respect to certain other privacy breaches and has responded to requests for information from the OCR. NMHC is unable to determine whether any corrective actions or fines might be imposed by OCR as a result of the disclosures or responses provided to OCR.

Litigation

Northwestern Memorial is a defendant in various other lawsuits arising in the ordinary course of business. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on Northwestern Memorial's consolidated financial position or operations.

15. Subsequent Events

Northwestern Memorial evaluated events and transactions occurring subsequent to August 31, 2025 through November 11, 2025, the date of issuance of these condensed consolidated financial statements. During this period, there were no subsequent events requiring recognition in the condensed consolidated financial statements and no unrecognized subsequent events requiring disclosure other than that disclosed in Note 3 and Note 6.